TY - JOUR AU - Vose, J. M. PY - 2017 DA - 2017// TI - Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management JO - American Journal of Hematology. VL - 92 UR - https://doi.org/10.1002/ajh.24797 DO - 10.1002/ajh.24797 ID - Vose2017 ER - TY - JOUR AU - Maddocks, K. PY - 2018 DA - 2018// TI - Update on mantle cell lymphoma JO - Blood. VL - 132 UR - https://doi.org/10.1182/blood-2018-03-791392 DO - 10.1182/blood-2018-03-791392 ID - Maddocks2018 ER - TY - JOUR AU - Nodit, L. AU - Bahler, D. W. AU - Jacobs, S. A. AU - Locker, J. AU - Swerdlow, S. H. PY - 2003 DA - 2003// TI - Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes JO - Human Pathology. VL - 34 UR - https://doi.org/10.1053/S0046-8177(03)00410-6 DO - 10.1053/S0046-8177(03)00410-6 ID - Nodit2003 ER - TY - JOUR AU - Orchard, J. AU - Garand, R. AU - Davis, Z. AU - Babbage, G. AU - Sahota, S. AU - Matutes, E. PY - 2003 DA - 2003// TI - A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease JO - Blood. VL - 101 UR - https://doi.org/10.1182/blood-2002-06-1864 DO - 10.1182/blood-2002-06-1864 ID - Orchard2003 ER - TY - JOUR AU - Eve, H. E. AU - Furtado, M. V. AU - Hamon, M. D. AU - Rule, S. A. J. PY - 2009 DA - 2009// TI - Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.23.9731 DO - 10.1200/JCO.2009.23.9731 ID - Eve2009 ER - TY - JOUR AU - Martin, P. AU - Chadburn, A. AU - Christos, P. AU - Weil, K. AU - Furman, R. R. AU - Ruan, J. PY - 2009 DA - 2009// TI - Outcome of deferred initial therapy in mantle-cell lymphoma JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.6121 DO - 10.1200/JCO.2008.19.6121 ID - Martin2009 ER - TY - JOUR AU - McKay, P. AU - Leach, M. AU - Jackson, B. AU - Robinson, S. AU - Rule, S. PY - 2018 DA - 2018// TI - Guideline for the management of mantle cell lymphoma JO - Br J Haematol VL - 182 UR - https://doi.org/10.1111/bjh.15283 DO - 10.1111/bjh.15283 ID - McKay2018 ER - TY - JOUR AU - Cheah, C. Y. AU - Seymour, J. F. AU - Wang, M. L. PY - 2016 DA - 2016// TI - Mantle cell lymphoma JO - Journal of Clinical Oncology. VL - 34 UR - https://doi.org/10.1200/JCO.2015.63.5904 DO - 10.1200/JCO.2015.63.5904 ID - Cheah2016 ER - TY - JOUR AU - Swerdlow, S. H. AU - Campo, E. AU - Pileri, S. A. AU - Harris, N. L. AU - Stein, H. AU - Siebert, R. PY - 2016 DA - 2016// TI - The 2016 revision of the World Health Organization classification of lymphoid neoplasms JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2016-01-643569 DO - 10.1182/blood-2016-01-643569 ID - Swerdlow2016 ER - TY - STD TI - National Comprehensive Cancer Network. B-cell lymphomas. NCCN Guidelines Version 4.2019. 2019. ID - ref10 ER - TY - JOUR AU - Dreyling, M. AU - Campo, E. AU - Hermine, O. AU - Jerkeman, M. AU - Gouill, S. AU - Rule, S. PY - 2017 DA - 2017// TI - Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx223 DO - 10.1093/annonc/mdx223 ID - Dreyling2017 ER - TY - JOUR AU - Miao, Y. AU - Cao, L. AU - Sun, Q. AU - Li, X. -. T. AU - Wang, Y. AU - Qiao, C. PY - 2017 DA - 2017// TI - Spectrum and immunophenotyping of 653 patients with B-cell chronic lymphoproliferative disorders in China: a single-centre analysis JO - Hematol Oncol VL - 36 UR - https://doi.org/10.1002/hon.2461 DO - 10.1002/hon.2461 ID - Miao2017 ER - TY - STD TI - Prevalence of lymphoma subtypes in Shanxi according to latest WHO classification. Chin J Pathol. 2006;35(4):218-23. ID - ref13 ER - TY - JOUR AU - Meng, J. AU - Chang, C. AU - Pan, H. AU - Zhu, F. AU - Xiao, Y. AU - Liu, T. PY - 2018 DA - 2018// TI - Epidemiologic characteristics of malignant lymphoma in Hubei JO - China. Medicine. VL - 97 ID - Meng2018 ER - TY - JOUR AU - Wang, J. AU - Young, L. AU - Win, W. AU - Taylor, C. R. PY - 2005 DA - 2005// TI - Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique JO - Appl Immunohistochem Mol Morphol VL - 13 UR - https://doi.org/10.1097/01.pai.0000176161.38402.b2 DO - 10.1097/01.pai.0000176161.38402.b2 ID - Wang2005 ER - TY - JOUR AU - Wu, Y. AU - Wang, H. AU - Liu, X. -. J. AU - Wang, Y. -. Y. AU - Zhao, W. -. L. AU - Li, J. -. M. PY - 2017 DA - 2017// TI - Clinical characteristics and outcome of 66 cases of mantle cell lymphomas JO - Zhongguo shi yan xue ye xue za zhi. VL - 25 ID - Wu2017 ER - TY - JOUR AU - Chim, C. S. AU - Chan, A. C. L. AU - Choo, C. K. AU - Kwong, Y. L. AU - Lie, A. K. W. AU - Liang, R. PY - 1998 DA - 1998// TI - Mantle cell lymphoma in the Chinese: clinicopathological features and treatment outcome JO - Am J Hematol VL - 59 UR - https://doi.org/3.0.CO;2-N DO - 3.0.CO;2-N ID - Chim1998 ER - TY - JOUR AU - Anderson, J. R. AU - Armitage, J. O. AU - Weisenburger, D. D. PY - 1998 DA - 1998// TI - For the Non-Hodgkin’s Lymphoma Classification P. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations JO - Ann Oncol VL - 9 UR - https://doi.org/10.1023/A:1008265532487 DO - 10.1023/A:1008265532487 ID - Anderson1998 ER - TY - JOUR AU - Lee, M. -. Y. AU - Tan, T. -. D. AU - Feng, A. -. C. AU - Liu, M. -. C. PY - 2006 DA - 2006// TI - Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution JO - Am J Hematol VL - 81 UR - https://doi.org/10.1002/ajh.20649 DO - 10.1002/ajh.20649 ID - Lee2006 ER - TY - JOUR AU - Kim, J. -. M. AU - Ko, Y. -. H. AU - Lee, S. -. S. AU - Huh, J. AU - Kang, C. S. AU - Kim, C. W. PY - 2011 DA - 2011// TI - WHO classification of malignant lymphomas in Korea: report of the third nationwide study JO - Kor J Pathol VL - 45 UR - https://doi.org/10.4132/KoreanJPathol.2011.45.3.254 DO - 10.4132/KoreanJPathol.2011.45.3.254 ID - Kim2011 ER - TY - JOUR AU - Lee, H. AU - Park, H. J. AU - Park, E. -. H. AU - Ju, H. Y. AU - Oh, C. -. M. AU - Kong, H. -. J. PY - 2018 DA - 2018// TI - Nationwide statistical analysis of lymphoid malignancies in Korea JO - Cancer Res Treat VL - 50 UR - https://doi.org/10.4143/crt.2017.093 DO - 10.4143/crt.2017.093 ID - Lee2018 ER - TY - JOUR AU - Miyoshi, H. AU - Ohshima, K. PY - 2018 DA - 2018// TI - Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan JO - Int J Hematol VL - 107 UR - https://doi.org/10.1007/s12185-018-2430-6 DO - 10.1007/s12185-018-2430-6 ID - Miyoshi2018 ER - TY - JOUR AU - Ohshima, K. PY - 1998 DA - 1998// TI - B-Cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification JO - Cancer Letters. VL - 135 UR - https://doi.org/10.1016/S0304-3835(98)00278-X DO - 10.1016/S0304-3835(98)00278-X ID - Ohshima1998 ER - TY - JOUR AU - Lim, R. B. T. AU - Loy, E. Y. AU - Lim, G. H. AU - Zheng, H. AU - Chow, K. Y. AU - Lim, S. T. PY - 2015 DA - 2015// TI - Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: secular trends of a population-based cancer registry from 1998 to 2012 JO - Int J Cancer. VL - 137 UR - https://doi.org/10.1002/ijc.29635 DO - 10.1002/ijc.29635 ID - Lim2015 ER - TY - JOUR AU - Chuang, S. S. PY - 2006 DA - 2006// TI - Striking male predominance of mantle cell lymphoma in Taiwan JO - J Clin Pathol VL - 59 UR - https://doi.org/10.1136/jcp.2005.035071 DO - 10.1136/jcp.2005.035071 ID - Chuang2006 ER - TY - JOUR AU - Chuang, S. -. S. AU - Huang, W. -. T. AU - Hsieh, P. -. P. AU - Tseng, H. -. H. AU - Campo, E. AU - Colomer, D. PY - 2006 DA - 2006// TI - Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2 JO - Pathol Int VL - 56 UR - https://doi.org/10.1111/j.1440-1827.2006.01986.x DO - 10.1111/j.1440-1827.2006.01986.x ID - Chuang2006 ER - TY - JOUR AU - Kang, B. W. AU - Sohn, S. K. AU - Moon, J. H. AU - Chae, Y. S. AU - Kim, J. G. AU - Lee, S. J. PY - 2014 DA - 2014// TI - Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the consortium for improving survival of lymphoma JO - Blood Res VL - 49 UR - https://doi.org/10.5045/br.2014.49.1.15 DO - 10.5045/br.2014.49.1.15 ID - Kang2014 ER - TY - JOUR AU - Yeoh, A. E. AU - Tan, D. AU - Li, C. K. AU - Hori, H. AU - Tse, E. AU - Pui, C. H. PY - 2013 DA - 2013// TI - Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013 JO - Lancet Oncol. VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70452-2 DO - 10.1016/S1470-2045(13)70452-2 ID - Yeoh2013 ER - TY - JOUR AU - Tan, D. AU - Tan, S. Y. AU - Lim, S. T. AU - Kim, S. J. AU - Kim, W. S. AU - Advani, R. PY - 2013 DA - 2013// TI - Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines JO - Lancet Oncol. VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70450-9 DO - 10.1016/S1470-2045(13)70450-9 ID - Tan2013 ER - TY - JOUR AU - Abrahamsson, A. AU - Albertsson-Lindblad, A. AU - Brown, P. N. AU - Baumgartner-Wennerholm, S. AU - Pedersen, L. M. AU - D’Amore, F. PY - 2014 DA - 2014// TI - Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study JO - Blood. VL - 124 UR - https://doi.org/10.1182/blood-2014-03-559930 DO - 10.1182/blood-2014-03-559930 ID - Abrahamsson2014 ER - TY - STD TI - Jo JC, Kim SJ, Lee HS, Eom HS, Lee SI, Park Y, et al. Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: consortium for improving survival of lymphoma report. Ann Hematol. 2019. ID - ref31 ER - TY - JOUR AU - Dabaja, B. S. AU - Zelenetz, A. D. AU - Ng, A. K. AU - Tsang, R. W. AU - Qi, S. AU - Allen, P. K. PY - 2017 DA - 2017// TI - Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG) JO - Ann Oncol. VL - 28 UR - https://doi.org/10.1093/annonc/mdx334 DO - 10.1093/annonc/mdx334 ID - Dabaja2017 ER - TY - JOUR AU - Dreyling, M. PY - 2005 DA - 2005// TI - Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network JO - Blood. VL - 105 UR - https://doi.org/10.1182/blood-2004-10-3883 DO - 10.1182/blood-2004-10-3883 ID - Dreyling2005 ER - TY - JOUR AU - Gouill, S. AU - Thieblemont, C. AU - Oberic, L. AU - Moreau, A. AU - Bouabdallah, K. AU - Dartigeas, C. PY - 2017 DA - 2017// TI - Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1701769 DO - 10.1056/NEJMoa1701769 ID - Gouill2017 ER - TY - JOUR AU - Khouri, I. F. AU - Romaguera, J. AU - Kantarjian, H. AU - Palmer, J. L. AU - Pugh, W. C. AU - Korbling, M. PY - 1998 DA - 1998// TI - Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma JO - J Clin Oncol VL - 16 UR - https://doi.org/10.1200/JCO.1998.16.12.3803 DO - 10.1200/JCO.1998.16.12.3803 ID - Khouri1998 ER - TY - JOUR AU - Geisler, C. H. AU - Kolstad, A. AU - Laurell, A. AU - Andersen, N. S. AU - Pedersen, L. B. AU - Jerkeman, M. PY - 2008 DA - 2008// TI - Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group JO - Blood. VL - 112 UR - https://doi.org/10.1182/blood-2008-03-147025 DO - 10.1182/blood-2008-03-147025 ID - Geisler2008 ER - TY - JOUR AU - Delarue, R. AU - Haioun, C. AU - Ribrag, V. AU - Brice, P. AU - Delmer, A. AU - Tilly, H. PY - 2013 DA - 2013// TI - CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte JO - Blood. VL - 121 UR - https://doi.org/10.1182/blood-2011-09-370320 DO - 10.1182/blood-2011-09-370320 ID - Delarue2013 ER - TY - JOUR AU - Hermine, O. AU - Hoster, E. AU - Walewski, J. AU - Bosly, A. AU - Stilgenbauer, S. AU - Thieblemont, C. PY - 2016 DA - 2016// TI - Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network JO - The Lancet. VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)00739-X DO - 10.1016/S0140-6736(16)00739-X ID - Hermine2016 ER - TY - JOUR AU - Armand, P. AU - Redd, R. AU - Bsat, J. AU - Mayuram, S. AU - Giardino, A. AU - Fisher, D. C. PY - 2016 DA - 2016// TI - A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma JO - Br J Haematol VL - 173 UR - https://doi.org/10.1111/bjh.13929 DO - 10.1111/bjh.13929 ID - Armand2016 ER - TY - JOUR AU - Chen, R. W. AU - Li, H. AU - Bernstein, S. H. AU - Kahwash, S. AU - Rimsza, L. M. AU - Forman, S. J. PY - 2017 DA - 2017// TI - RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106 JO - Br J Haematol. VL - 176 UR - https://doi.org/10.1111/bjh.14480 DO - 10.1111/bjh.14480 ID - Chen2017 ER - TY - JOUR AU - Mallet, V. AU - Bömmel, F. AU - Doerig, C. AU - Pischke, S. AU - Hermine, O. AU - Locasciulli, A. PY - 2016 DA - 2016// TI - Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European conference on infections in leukaemia (ECIL-5) JO - Lancet Infect Dis VL - 16 UR - https://doi.org/10.1016/S1473-3099(16)00118-3 DO - 10.1016/S1473-3099(16)00118-3 ID - Mallet2016 ER - TY - JOUR AU - Miura, K. AU - Takasaki, H. AU - Tsujimura, H. AU - Kanno, M. AU - Maeda, Y. AU - Tomita, N. PY - 2011 DA - 2011// TI - Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan JO - Int J Hematol VL - 93 UR - https://doi.org/10.1007/s12185-011-0845-4 DO - 10.1007/s12185-011-0845-4 ID - Miura2011 ER - TY - JOUR AU - Schulz, H. AU - Bohlius, J. F. AU - Trelle, S. AU - Skoetz, N. AU - Reiser, M. AU - Kober, T. PY - 2007 DA - 2007// TI - Immunochemotherapy With rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis JO - J Natl Cancer Inst VL - 99 UR - https://doi.org/10.1093/jnci/djk152 DO - 10.1093/jnci/djk152 ID - Schulz2007 ER - TY - JOUR AU - Lenz, G. AU - Dreyling, M. AU - Hoster, E. AU - Wörmann, B. AU - Dührsen, U. AU - Metzner, B. PY - 2005 DA - 2005// TI - Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low Grade Lymphoma Study Group (GLSG) JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.08.133 DO - 10.1200/JCO.2005.08.133 ID - Lenz2005 ER - TY - JOUR AU - Kluin-Nelemans, H. C. AU - Hoster, E. AU - Hermine, O. AU - Walewski, J. AU - Trneny, M. AU - Geisler, C. H. PY - 2012 DA - 2012// TI - Treatment of older patients with mantle-cell lymphoma JO - J Clin Oncol VL - 367 ID - Kluin-Nelemans2012 ER - TY - JOUR AU - Rummel, M. J. AU - Niederle, N. AU - Maschmeyer, G. AU - Banat, G. A. AU - Grünhagen, U. AU - Losem, C. PY - 2013 DA - 2013// TI - Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial JO - The Lancet. VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61763-2 DO - 10.1016/S0140-6736(12)61763-2 ID - Rummel2013 ER - TY - JOUR AU - Robak, T. AU - Huang, H. AU - Jin, J. AU - Zhu, J. AU - Liu, T. AU - Samoilova, O. PY - 2015 DA - 2015// TI - Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412096 DO - 10.1056/NEJMoa1412096 ID - Robak2015 ER - TY - JOUR AU - Ruan, J. AU - Martin, P. AU - Shah, B. AU - Schuster, S. J. AU - Smith, S. M. AU - Furman, R. R. PY - 2015 DA - 2015// TI - Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma JO - N Eng J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1505237 DO - 10.1056/NEJMoa1505237 ID - Ruan2015 ER - TY - JOUR AU - Ghielmini, M. AU - Schmitz, S. -. F. H. AU - Cogliatti, S. AU - Bertoni, F. AU - Waltzer, U. AU - Fey, M. F. PY - 2005 DA - 2005// TI - Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK) JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.04.164 DO - 10.1200/JCO.2005.04.164 ID - Ghielmini2005 ER - TY - JOUR AU - Jin, J. AU - Okamoto, R. AU - Yoon, S. -. S. AU - Shih, L. -. Y. AU - Zhu, J. AU - Liu, T. PY - 2018 DA - 2018// TI - Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma JO - Onco Targets Ther VL - 11 UR - https://doi.org/10.2147/OTT.S150339 DO - 10.2147/OTT.S150339 ID - Jin2018 ER - TY - JOUR AU - Ogura, M. AU - Ishizawa, K. AU - Maruyama, D. AU - Uike, N. AU - Ando, K. AU - Izutsu, K. PY - 2016 DA - 2016// TI - Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan JO - Int J Hematol VL - 105 UR - https://doi.org/10.1007/s12185-016-2146-4 DO - 10.1007/s12185-016-2146-4 ID - Ogura2016 ER - TY - JOUR AU - Abkur, T. M. AU - Saeed, M. AU - Ahmed, S. Z. AU - McArthur, R. AU - Leahy, M. AU - O’Leary, H. PY - 2015 DA - 2015// TI - Pneumocystis jiroveci prophylaxis in patients undergoing bendamustine treatment: the need for a standardized protocol JO - Clin Case Reports. VL - 3 UR - https://doi.org/10.1002/ccr3.195 DO - 10.1002/ccr3.195 ID - Abkur2015 ER - TY - JOUR AU - Budde, L. E. AU - Guthrie, K. A. AU - Till, B. G. AU - Press, O. W. AU - Chauncey, T. R. AU - Pagel, J. M. PY - 2011 DA - 2011// TI - Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.7055 DO - 10.1200/JCO.2010.33.7055 ID - Budde2011 ER - TY - JOUR AU - Geisler, C. H. AU - Kolstad, A. AU - Laurell, A. AU - Jerkeman, M. AU - Räty, R. AU - Andersen, N. S. PY - 2012 DA - 2012// TI - Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur JO - Br J Haematol VL - 158 UR - https://doi.org/10.1111/j.1365-2141.2012.09174.x DO - 10.1111/j.1365-2141.2012.09174.x ID - Geisler2012 ER - TY - JOUR AU - Krüger, W. H. AU - Hirt, C. AU - Basara, N. AU - Sayer, H. G. AU - Behre, G. AU - Fischer, T. PY - 2014 DA - 2014// TI - Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO) JO - Ann Hematol VL - 93 UR - https://doi.org/10.1007/s00277-014-2087-z DO - 10.1007/s00277-014-2087-z ID - Krüger2014 ER - TY - JOUR AU - Hamadani, M. AU - Saber, W. AU - Ahn, K. W. AU - Carreras, J. AU - Cairo, M. S. AU - Fenske, T. S. PY - 2013 DA - 2013// TI - Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research JO - Biol Blood Marrow Transplant VL - 19 UR - https://doi.org/10.1016/j.bbmt.2013.01.009 DO - 10.1016/j.bbmt.2013.01.009 ID - Hamadani2013 ER - TY - JOUR AU - Dietrich, S. AU - Finel, H. AU - Boumendil, A. AU - Avivi, I. AU - Volin, L. AU - Cornelissen, J. PY - 2012 DA - 2012// TI - Outcome and prognostic factors in patients with mantle cell lymphoma relapsing after autologous stem cell transplantation: a retrospective study of the EBMT JO - Blood VL - 120 UR - https://doi.org/10.1182/blood.V120.21.474.474 DO - 10.1182/blood.V120.21.474.474 ID - Dietrich2012 ER - TY - JOUR AU - Graf, S. A. AU - Stevenson, P. A. AU - Holmberg, L. A. AU - Till, B. G. AU - Press, O. W. AU - Chauncey, T. R. PY - 2014 DA - 2014// TI - Rituximab maintenance therapy after autologous stem cell transplantation improves survival of patients with mantle cell lymphoma JO - Blood VL - 124 UR - https://doi.org/10.1182/blood.V124.21.3985.3985 DO - 10.1182/blood.V124.21.3985.3985 ID - Graf2014 ER - TY - JOUR AU - Dietrich, S. AU - Weidle, J. AU - Rieger, M. AU - Meissner, J. AU - Radujkovic, A. AU - Ho, A. D. PY - 2013 DA - 2013// TI - Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma JO - Leukemia. VL - 28 UR - https://doi.org/10.1038/leu.2013.332 DO - 10.1038/leu.2013.332 ID - Dietrich2013 ER - TY - JOUR AU - Smith, M. R. AU - Li, H. AU - Gordon, L. AU - Gascoyne, R. D. AU - Paietta, E. AU - Forero-Torres, A. PY - 2012 DA - 2012// TI - Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90–ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499 JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2012.42.2444 DO - 10.1200/JCO.2012.42.2444 ID - Smith2012 ER - TY - JOUR AU - Vidal, L. AU - Gafter-Gvili, A. AU - Dreyling, M. AU - Ghielmini, M. AU - Witzens-Harig, M. AU - Shpilberg, O. PY - 2018 DA - 2018// TI - Maintenance treatment for patients with mantle cell lymphoma JO - HemaSphere. VL - 2 UR - https://doi.org/10.1097/HS9.0000000000000136 DO - 10.1097/HS9.0000000000000136 ID - Vidal2018 ER - TY - JOUR AU - Wang, M. L. AU - Lee, H. AU - Chuang, H. AU - Wagner-Bartak, N. AU - Hagemeister, F. AU - Westin, J. PY - 2016 DA - 2016// TI - Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial JO - The Lancet Oncology. VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00438-6 DO - 10.1016/S1470-2045(15)00438-6 ID - Wang2016 ER - TY - JOUR AU - Dreyling, M. AU - Jurczak, W. AU - Jerkeman, M. AU - Silva, R. S. AU - Rusconi, C. AU - Trneny, M. PY - 2016 DA - 2016// TI - Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study JO - The Lancet. VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)00667-4 DO - 10.1016/S0140-6736(15)00667-4 ID - Dreyling2016 ER - TY - JOUR AU - Wang, M. L. AU - Rule, S. AU - Martin, P. AU - Goy, A. AU - Auer, R. AU - Kahl, B. S. PY - 2013 DA - 2013// TI - Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1306220 DO - 10.1056/NEJMoa1306220 ID - Wang2013 ER - TY - JOUR AU - Zinzani, P. L. AU - Vose, J. M. AU - Czuczman, M. S. AU - Reeder, C. B. AU - Haioun, C. AU - Polikoff, J. PY - 2013 DA - 2013// TI - Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt366 DO - 10.1093/annonc/mdt366 ID - Zinzani2013 ER - TY - JOUR AU - Goy, A. AU - Sinha, R. AU - Williams, M. E. AU - Kalayoglu Besisik, S. AU - Drach, J. AU - Ramchandren, R. PY - 2013 DA - 2013// TI - Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.49.2835 DO - 10.1200/JCO.2013.49.2835 ID - Goy2013 ER - TY - JOUR AU - Trněný, M. AU - Lamy, T. AU - Walewski, J. AU - Belada, D. AU - Mayer, J. AU - Radford, J. PY - 2016 DA - 2016// TI - Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial JO - The Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00559-8 DO - 10.1016/S1470-2045(15)00559-8 ID - Trněný2016 ER - TY - JOUR AU - Rule, S. AU - Jurczak, W. AU - Jerkeman, M. AU - Rusconi, C. AU - Trneny, M. AU - Offner, F. PY - 2018 DA - 2018// TI - Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study JO - Leukemia. VL - 32 UR - https://doi.org/10.1038/s41375-018-0023-2 DO - 10.1038/s41375-018-0023-2 ID - Rule2018 ER - TY - JOUR AU - Rule, S. AU - Dreyling, M. AU - Goy, A. AU - Hess, G. AU - Auer, R. AU - Kahl, B. PY - 2018 DA - 2018// TI - Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis JO - Haematologica. VL - 104 UR - https://doi.org/10.3324/haematol.2018.205229 DO - 10.3324/haematol.2018.205229 ID - Rule2018 ER - TY - JOUR AU - Fisher, R. I. AU - Bernstein, S. H. AU - Kahl, B. S. AU - Djulbegovic, B. AU - Robertson, M. J. AU - Vos, S. PY - 2006 DA - 2006// TI - Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.07.9665 DO - 10.1200/JCO.2006.07.9665 ID - Fisher2006 ER - TY - JOUR AU - Agathocleous, A. AU - Rohatiner, A. AU - Rule, S. AU - Hunter, H. AU - Kerr, J. P. AU - Neeson, S. M. PY - 2010 DA - 2010// TI - Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia JO - Br J Haematol VL - 151 UR - https://doi.org/10.1111/j.1365-2141.2010.08340.x DO - 10.1111/j.1365-2141.2010.08340.x ID - Agathocleous2010 ER - TY - JOUR AU - Wang, M. AU - Fayad, L. AU - Wagner-Bartak, N. AU - Zhang, L. AU - Hagemeister, F. AU - Neelapu, S. S. PY - 2012 DA - 2012// TI - Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial JO - The Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70200-0 DO - 10.1016/S1470-2045(12)70200-0 ID - Wang2012 ER - TY - JOUR AU - Wang, M. AU - Rule, S. AU - Zinzani, P. L. AU - Goy, A. AU - Casasnovas, O. AU - Smith, S. D. PY - 2018 DA - 2018// TI - Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial JO - The Lancet. VL - 391 UR - https://doi.org/10.1016/S0140-6736(17)33108-2 DO - 10.1016/S0140-6736(17)33108-2 ID - Wang2018 ER - TY - JOUR AU - Tam, C. S. AU - Wang, M. AU - Simpson, D. AU - Opat, S. AU - Cull, G. AU - Munoz, J. PY - 2019 DA - 2019// TI - Updated Safety and efficacy data in in the phase 1 trial of patients with mantle cell lymphoma (MCL) treated with Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) JO - Hematol Oncol VL - 37 UR - https://doi.org/10.1002/hon.55_2630 DO - 10.1002/hon.55_2630 ID - Tam2019 ER - TY - JOUR AU - Tobinai, K. PY - 2002 DA - 2002// TI - Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan JO - International Journal of Hematology. VL - 76 UR - https://doi.org/10.1007/BF02982806 DO - 10.1007/BF02982806 ID - Tobinai2002 ER - TY - JOUR AU - Igarashi, T. AU - Kobayashi, Y. AU - Ogura, M. AU - Kinoshita, T. AU - Ohtsu, T. AU - Sasaki, Y. PY - 2002 DA - 2002// TI - Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study JO - Ann Oncol VL - 13 UR - https://doi.org/10.1093/annonc/mdf155 DO - 10.1093/annonc/mdf155 ID - Igarashi2002 ER - TY - JOUR AU - Tobinai, K. AU - Uchida, T. AU - Fukuhara, N. AU - Nishikawa, T. PY - 2019 DA - 2019// TI - Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study JO - Int J Hematol VL - 109 UR - https://doi.org/10.1007/s12185-018-02577-8 DO - 10.1007/s12185-018-02577-8 ID - Tobinai2019 ER - TY - JOUR AU - Maruyama, D. AU - Nagai, H. AU - Fukuhara, N. AU - Kitano, T. AU - Ishikawa, T. AU - Nishikawa, T. PY - 2019 DA - 2019// TI - Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma JO - J Clin Exp Hematop VL - 59 UR - https://doi.org/10.3960/jslrt.19006 DO - 10.3960/jslrt.19006 ID - Maruyama2019 ER - TY - JOUR AU - Jeon, Y. W. AU - Yoon, S. AU - Min, G. J. AU - Park, S. S. AU - Park, S. AU - Yoon, J. H. PY - 2019 DA - 2019// TI - Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience JO - Cancer Medicine. VL - 8 UR - https://doi.org/10.1002/cam4.2565 DO - 10.1002/cam4.2565 ID - Jeon2019 ER - TY - STD TI - Yi JH, Kim WS, Kim SJ, Yoon DH, Suh C, Chang MH, et al. LBA13Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis. Ann Oncol. 2019;30(Supplement_9). ID - ref80 ER - TY - JOUR AU - Nazha, B. AU - Mishra, M. AU - Pentz, R. AU - Owonikoko, T. K. PY - 2019 DA - 2019// TI - Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy JO - Am Soc Clin Oncol Educ Book VL - 39 UR - https://doi.org/10.1200/EDBK_100021 DO - 10.1200/EDBK_100021 ID - Nazha2019 ER -